← Leaderboards
Laura Carpin Kennedy
Vanderbilt University Medical Center
$817,315
Attributed
$1,634,629
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $578K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,634,629 · 1
By mechanism
R01$1,634,629 · 1
Top collaborators
- Carlos L Arteaga3 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Metin Nafi Gurcan$7,482,153
- Alex G Waterson$938,173
- Megan Elizabeth Salwei$740,212
Others in their field
Other Rising Stars on “Adjuvant Chemotherapy”
- Kathryn Marie Jones · Baylor College Of Medicine$3,103,804
- Amy Fowler · University Of Wisconsin-Madison$3,008,001
- Alice Chia- Chi Wei · Sloan-Kettering Inst Can Research$2,617,533
- Nadine Norton · Mayo Clinic Jacksonville$2,431,858
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$2,101,095
- Nduka Mgbechinyere Amankulor · University Of Pennsylvania$2,082,285
Research focus
Adjuvant ChemotherapyCorrelative StudyAdjuvant TherapyAgonistAdjuvant Endocrine TherapyAdhesion ReceptorApoptosisAromatase InhibitorsAtac-SeqBiopsyBreast BiopsyBreast Cancer SurvivalBreast ConservationBreast-Conserving SurgeryCancer BurdenCancer SubtypesCaringCasp3 GeneCell AdhesionCell Cycle ArrestCellsChemotherapyClinical TrialsDeprivation
Grant awards (3)
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer$578,023
R01 · FY2025 · CA · contact PI
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer$546,296
R01 · FY2024 · CA · contact PI
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer$510,310
R01 · FY2023 · CA · contact PI